Chinese hamster ovary (CHO) cells have been the cell line of choice for producing most biotherapeutics. The dihydrofolate reductase (DHFR)-deficient CHO DG44 is a well characterized cell line that exhibits long-term stability and is a universally accepted platform in the industry for producing diverse monoclonal antibodies and proteins. However, there are different challenges faced by the biopharmaceutical industry while using the CHO DG44 platform, including prolonged timelines from gene synthesis to production of a research cell bank and the low product titers. Improved process design as well as vector modifications can help address both limitations to improve titers and to achieve faster results for expediting therapeutic objectives.
In the upcoming webinar, the featured speaker will lead a discussion on the development of new generation vectors and effective process improvements to increase the utility of CHO DG44 as a cell line development platform.
Register to learn about driving better titers and shorter timelines with a robust and scalable CHO DG44 platform.
Dr. Sufia Karim, Director, Cell Line Development, Aragen Life Sciences
Dr. Sufia Karim is Director of Cell Line Development & Late-Stage R&D at Aragen Bioscience, Inc. She has more than 18 years’ experience in the biotech industry, including leading cell line development, cell culture, process development & optimization and successful tech transfer. Dr. Karim previously worked with Boehringer Ingelheim and Amgen. She earned her MD from Sir Salimullah Medical College (Dhaka, Bangladesh) and her MS in molecular and microbiology from San Jose State University.Message Presenter
Who Should Attend?
- Scientists and business development personnel of pharmaceutical and biotechnology companies and virtual and other CROs involved in IND-enabling preclinical and clinical research activities
- Academic scientists working on CNS tumor research
What You Will Learn
Attendees will gain insights into:
- Challenges faced while using the dihydrofolate reductase (DHFR)-deficient CHO DG44 platform
- New generation vectors and process design improvements to improve CHO DG44 as a cell line development platform
Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. It offers end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, the Company operates through a network of sites located globally with a team of 3000+ scientists and 450+ PhDs. Its expertise and experience have enabled over 450 customers to advance their research programs from discovery through commercialization. Aragen’s innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma, biotech, agrochemical, animal health and performance chemical industries globally. Visit www.aragen.com for more details